Efficacy of epetraborole against Mycobacteroides abscessus in a mouse model of lung infection.

Autor: Rimal B; Division of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA., Lippincott CK; Division of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.; Center for Nontuberculous Mycobacteria and Bronchiectasis, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA., Panthi CM; Division of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA., Xie Y; Division of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA., Keepers TR; AN2 Therapeutics, Inc., Menlo Park, California, USA., Alley M; AN2 Therapeutics, Inc., Menlo Park, California, USA., Lamichhane G; Division of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.; Center for Nontuberculous Mycobacteria and Bronchiectasis, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.

Publikováno v: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2024 Aug 07; Vol. 68 (8), pp. e0064824. Date of Electronic Publication: 2024 Jul 17.

Activity of Omadacycline in Rat Methicillin-Resistant Staphylococcus aureus Osteomyelitis.

Autor: Karau MJ; Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinicgrid.66875.3a, Rochester, Minnesota, USA., Schmidt-Malan SM; Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinicgrid.66875.3a, Rochester, Minnesota, USA., Cunningham SA; Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinicgrid.66875.3a, Rochester, Minnesota, USA., Mandrekar JN; Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinicgrid.66875.3a, Rochester, Minnesota, USA., Pritt BS; Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinicgrid.66875.3a, Rochester, Minnesota, USA., Keepers TR; Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA., Serio AW; Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA., Chitra S; Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA., Patel R; Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinicgrid.66875.3a, Rochester, Minnesota, USA.; Division of Infectious Diseases, Department of Medicine, Mayo Clinicgrid.66875.3a, Rochester, Minnesota, USA.

Publikováno v: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2022 Jan 18; Vol. 66 (1), pp. e0170321. Date of Electronic Publication: 2021 Nov 01.

Once-Daily Plazomicin for Complicated Urinary Tract Infections.

Autor: Wagenlehner FME; From the Justus Liebig University, Giessen, Germany (F.M.E.W.); Achaogen, South San Francisco (D.J.C., A.S.K., D.S.C., K.M.K., T.R.K., L.E.C., I.F.), the David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles (L.G.M.), and Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance (L.G.M.) - all in California; and Vanderbilt University Medical Center, Nashville (J.P.D.)., Cloutier DJ; From the Justus Liebig University, Giessen, Germany (F.M.E.W.); Achaogen, South San Francisco (D.J.C., A.S.K., D.S.C., K.M.K., T.R.K., L.E.C., I.F.), the David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles (L.G.M.), and Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance (L.G.M.) - all in California; and Vanderbilt University Medical Center, Nashville (J.P.D.)., Komirenko AS; From the Justus Liebig University, Giessen, Germany (F.M.E.W.); Achaogen, South San Francisco (D.J.C., A.S.K., D.S.C., K.M.K., T.R.K., L.E.C., I.F.), the David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles (L.G.M.), and Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance (L.G.M.) - all in California; and Vanderbilt University Medical Center, Nashville (J.P.D.)., Cebrik DS; From the Justus Liebig University, Giessen, Germany (F.M.E.W.); Achaogen, South San Francisco (D.J.C., A.S.K., D.S.C., K.M.K., T.R.K., L.E.C., I.F.), the David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles (L.G.M.), and Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance (L.G.M.) - all in California; and Vanderbilt University Medical Center, Nashville (J.P.D.)., Krause KM; From the Justus Liebig University, Giessen, Germany (F.M.E.W.); Achaogen, South San Francisco (D.J.C., A.S.K., D.S.C., K.M.K., T.R.K., L.E.C., I.F.), the David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles (L.G.M.), and Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance (L.G.M.) - all in California; and Vanderbilt University Medical Center, Nashville (J.P.D.)., Keepers TR; From the Justus Liebig University, Giessen, Germany (F.M.E.W.); Achaogen, South San Francisco (D.J.C., A.S.K., D.S.C., K.M.K., T.R.K., L.E.C., I.F.), the David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles (L.G.M.), and Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance (L.G.M.) - all in California; and Vanderbilt University Medical Center, Nashville (J.P.D.)., Connolly LE; From the Justus Liebig University, Giessen, Germany (F.M.E.W.); Achaogen, South San Francisco (D.J.C., A.S.K., D.S.C., K.M.K., T.R.K., L.E.C., I.F.), the David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles (L.G.M.), and Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance (L.G.M.) - all in California; and Vanderbilt University Medical Center, Nashville (J.P.D.)., Miller LG; From the Justus Liebig University, Giessen, Germany (F.M.E.W.); Achaogen, South San Francisco (D.J.C., A.S.K., D.S.C., K.M.K., T.R.K., L.E.C., I.F.), the David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles (L.G.M.), and Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance (L.G.M.) - all in California; and Vanderbilt University Medical Center, Nashville (J.P.D.)., Friedland I; From the Justus Liebig University, Giessen, Germany (F.M.E.W.); Achaogen, South San Francisco (D.J.C., A.S.K., D.S.C., K.M.K., T.R.K., L.E.C., I.F.), the David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles (L.G.M.), and Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance (L.G.M.) - all in California; and Vanderbilt University Medical Center, Nashville (J.P.D.)., Dwyer JP; From the Justus Liebig University, Giessen, Germany (F.M.E.W.); Achaogen, South San Francisco (D.J.C., A.S.K., D.S.C., K.M.K., T.R.K., L.E.C., I.F.), the David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles (L.G.M.), and Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance (L.G.M.) - all in California; and Vanderbilt University Medical Center, Nashville (J.P.D.).

Publikováno v: The New England journal of medicine [N Engl J Med] 2019 Feb 21; Vol. 380 (8), pp. 729-740.

Effect of In Vitro Testing Parameters on Ceftazidime-Avibactam Minimum Inhibitory Concentrations.

Autor: Keepers TR; Cerexa, Inc., Oakland, CA 94612, USA., Gomez M; Cerexa, Inc., Oakland, CA 94612, USA., Biek D; Cerexa, Inc., Oakland, CA 94612, USA., Critchley I; Cerexa, Inc., Oakland, CA 94612, USA., Krause KM; Cerexa, Inc., Oakland, CA 94612, USA.

Publikováno v: International scholarly research notices [Int Sch Res Notices] 2015 May 19; Vol. 2015, pp. 489547. Date of Electronic Publication: 2015 May 19 (Print Publication: 2015).

A systematic screen of FDA-approved drugs for inhibitors of biological threat agents.

Autor: Madrid PB; Center for Infectious Disease and Biodefense Research, SRI International, Menlo Park, California, USA. peter.madrid@sri.com, Chopra S, Manger ID, Gilfillan L, Keepers TR, Shurtleff AC, Green CE, Iyer LV, Dilks HH, Davey RA, Kolokoltsov AA, Carrion R Jr, Patterson JL, Bavari S, Panchal RG, Warren TK, Wells JB, Moos WH, Burke RL, Tanga MJ

Publikováno v: PloS one [PLoS One] 2013; Vol. 8 (4), pp. e60579. Date of Electronic Publication: 2013 Apr 05.